Just caught up on OPK's Q4 earnings and there's some interesting stuff happening with this healthcare play. The company beat on earnings per share but revenues came in at $148.5 million, down about 19% year-over-year. Not exactly inspiring at first glance, but the story gets more nuanced when you dig into the segments.

The diagnostics side took a hit, with services revenue dropping 30.5% mainly because of the BioReference asset sale to Labcorp. That was a deliberate move though - they're focusing their clinical lab business on core operations and expanding their 4Kscore franchise, which actually grew volumes in the quarter. The pharma arm showed some strength with product revenues up 16.8% year-over-year, hitting $43.7 million, though Rayaldee sales slipped 3.3%.

What caught my attention is the margin compression. Gross margin contracted 290 basis points to 43.2%, which reflects the transition happening across the business. Operating loss widened to $38.3 million from $33.1 million in the prior year. But management seems confident about the restructuring - they're guiding for Q1 2026 revenues between $125-140 million and full-year 2026 revenues of $530-560 million.

OPK is banking on some meaningful catalysts here. The Regeneron partnership has potential milestone value exceeding $1 billion, and they're getting royalty contributions from Lilly's mazdutide launch in China. Plus the therapeutics division has multiple programs advancing, including MDX2001 and MDX2004. They exited with $369.1 million in cash, down from $428.9 million last quarter, but that's expected given the operating losses.

The real question is whether this transformation actually delivers. They're positioning as a leaner, more focused operation after shedding oncology assets, but earnings still need to stabilize. Worth monitoring for the next couple quarters to see if those clinical catalysts and cost cuts actually move the needle.